Exenatide for Myocardial Protection During Reperfusion Study
NCT01938235 on ClinicalTrials.gov · last registry update 2016-08-05
198 participants. Its estimated completion date, July 2017, has passed with no update to the record. Primary outcome, as filed: Ratio of final infarct size at 3 months over area at risk at 72 hours post randomization (using cMRI). A lapsed estimate is not a result and not a failure — sponsors are slow to refile — but ClinicalTrials.gov marks it nowhere on the record, so it is noted here. exenatide is approved in the US, but not for cardiovascular disease — a registration here is not an approval, and most drugs tested in a new condition never get one for it.
- Status
- UNKNOWN
- Phase
- P2
- Drug
- exenatideBydureon, Byetta
- Sponsor type
- Other
- Enrollment
- 198
- Started
- 2014-02
- Primary completion
- 2017-07 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Ratio of final infarct size at 3 months over area at risk at 72 hours post randomization (using cMRI)
Conditions studied
Myocardial Infarction
Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.